Physician profile
Randy I Pardell
NPI 1578516969
$5,311.69
in general payments reported to CMS, 2019-2025
25 companies · $658 in 2025
The $658 reported for 2025 was more than what 75% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,005 · 2020: $494 · 2021: $347 · 2022: $111 · 2023: $457 · 2024: $2,239 · 2025: $658.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,144 · Travel and Lodging: $1,211.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,143.55 |
| Travel and Lodging | $1,210.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $2,073.87 | 2019-2024 | Spravato |
| Abbvie INC. | $1,058.91 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $319.80 | 2019-2025 | Austedo Xr, Austedo Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $202.07 | 2020-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $180.32 | 2019-2024 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Lundbeck LLC | $180.26 | 2019-2024 | Rexulti |
| Corium, LLC | $167.95 | 2023-2025 | Azstarys |
| Neuronetics, INC. | $140.46 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $131.19 | 2019-2023 | Trintellix |
| Alkermes, INC. | $107.20 | 2024-2025 | Lybalvi, Aristada |
| E.R. Squibb & Sons, L.L.C. | $95.81 | 2025 | Cobenfy |
| Axsome Therapeutics, INC. | $89.67 | 2024 | Auvelity |
| Neurocrine Biosciences, INC. | $81.66 | 2024-2025 | Ingrezza |
| Vanda Pharmaceuticals INC. | $80.07 | 2023 | Fanapt, Hetlioz |
| Avanir Pharmaceuticals, INC. | $75.89 | 2019-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $66.11 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $60.91 | 2019-2020 | |
| Ironshore Pharmaceuticals INC. | $49.98 | 2019 | |
| Bausch Health US, LLC | $36.56 | 2019-2020 | |
| Eisai INC. | $22.97 | 2020 | |
| Vertical Pharmaceuticals, LLC | $22.57 | 2019 | |
| Shire North American Group INC | $20.63 | 2019 | |
| Sunovion Pharmaceuticals INC. | $19.72 | 2020 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $14.01 | 2019 | |
| Alfasigma USA, INC. | $13.10 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Randy Pardell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.